--- title: "Nomura Sees Asian Companies Seizing Global GLP-1 Receptor Agonist Opportunities, Raises TPs for WUXI APPTEC and INNOVENT BIO" type: "News" locale: "en" url: "https://longbridge.com/en/news/292277228.md" description: "Nomura forecasts the global GLP-1 receptor agonist market to reach USD180 billion in a decade, driven by expansion into rest-of-world markets. Consequently, Nomura raised target prices for Wuxi AppTec (HKD157 to HKD180), Innovent Bio (HKD114.64 to HKD123.17), and Asymchem (HKD115.43 to HKD131.48), maintaining Buy ratings for all three companies." datetime: "2026-07-10T05:51:53.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292277228.md) - [en](https://longbridge.com/en/news/292277228.md) - [zh-HK](https://longbridge.com/zh-HK/news/292277228.md) generator: "portal-rs" --- # Nomura Sees Asian Companies Seizing Global GLP-1 Receptor Agonist Opportunities, Raises TPs for WUXI APPTEC and INNOVENT BIO Nomura published a report stating that growth in the market for GLP-1 receptor agonists (GLP-1 RAs) in the rest of the world (ROW) will drive significant expansion of the drug category. The global GLP-1 RAs market is currently valued at USD72 billion. According to third-party forecasts, the market size is expected to reach USD180 billion over the next decade, representing a CAGR of about 11%. In terms of geographic expansion, the extension from the highly profitable US market to ROW markets with lower pricing but large patient populations will become a major market driver. The broker noted that molecules under development feature greater safety, longer-lasting efficacy and fewer side effects, while indications are expanding beyond diabetes and obesity. The commercial success of GLP-1 RAs lies in their efficacy, enabling expansion from diabetes treatment into chronic weight management. Nomura raised the TP for WUXI APPTEC (02359.HK) +8.100 (+5.436%) Short selling $238.47M; Ratio 40.125% from HKD157.07 to HKD180.22, while maintaining a Buy rating; raised the TP for INNOVENT BIO (01801.HK) +4.200 (+4.864%) Short selling $191.17M; Ratio 26.252% from HKD114.64 to HKD123.17, while maintaining a Buy rating; and raised the TP for ASYMCHEM (06821.HK) +7.100 (+6.158%) Short selling $1.23M; Ratio 1.407% from HKD115.43 to HKD131.48, while maintaining a Buy rating. (su/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-10 12:25.) ### Related Stocks - [603259.CN](https://longbridge.com/en/quote/603259.CN.md) - [02359.HK](https://longbridge.com/en/quote/02359.HK.md) - [01801.HK](https://longbridge.com/en/quote/01801.HK.md) - [002821.CN](https://longbridge.com/en/quote/002821.CN.md) - [06821.HK](https://longbridge.com/en/quote/06821.HK.md) - [8604.JP](https://longbridge.com/en/quote/8604.JP.md) - [NMR.US](https://longbridge.com/en/quote/NMR.US.md) ## Related News & Research - [Innovent Biologics Grants Share Options and Restricted Shares Under 2024 Scheme](https://longbridge.com/en/news/297677279.md) - [WuXi AppTec files HKEX next-day disclosure return, share capital rises on 7,166,606 H-share conversion](https://longbridge.com/en/news/297883422.md) - [WuXi AppTec files HKEX next-day disclosure return reporting 6,827,131 new H shares from bond conversion](https://longbridge.com/en/news/298010654.md) - [Innovent Biologics files list of board, board committee members with disclosure duties](https://longbridge.com/en/news/297651124.md) - [Innovent Biologics grants 583,731 restricted shares under 2024 share scheme](https://longbridge.com/en/news/297669209.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**